Spyre’s arthritis misses; Ideaya ends eye cancer trial
Plus news about United Therapeutics. Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did not meet the primary endpoints in the psoriatic arthritis or ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.